StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
025620.KS$6000.00-4.76%
Fair $6000.00+0.0%

025620.KS

Cha AI Healthcare Co., Ltd.

Consumer Defensive / Household & Personal ProductsKSE

$6000.00

-300.00 (-4.76%)

Fairly Valued+0.0%Fair Value $6000.00Fund rank 29/100 · Data gapFallback financials|
SA 27/D
F-Score: 3/9
Declining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 22%

FCF escenarios

weak_data · normalized FCF $-7.3B · quality 62.3/100

Data gap 29/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 30/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

27/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 2 consecutive years ROE is 1.8%, below the 5% threshold
Thesis & Journal · 025620.KSLocal privado en este navegador · Cha AI Healthcare Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$48.1B

P/E

33.1x

↑

EV/EBITDA

12.2x

↑

ROE

1.8%

↓

Gross Margin

28.3%

↑

Debt/Equity

0.41

↑
52-Week Range$6000
$5870$19780

TradingView lightweight chart

025620.KS price, volumen y niveles de valoración

Último $6,000Periodo -100.0%
Fair value: $6,000

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+5.4%

FCF CAGR

—

FCF margin

-100.1%

FCF / Net income

-5.35x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $7.31B · net income $1.37B · FCF $-7.31B

2022-FY → 2025-FY

Gross margin

28.3%+13.8% pts

Operating margin

-97.2%+30.5% pts

Net margin

18.7%+361.9% pts

FCF margin

-100.1%+107.5% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$7.31B$7.31B$15.68B$16.09B$6.25B
Net Income$1.37B$1.37B$-9.49B$-6.80B$-21.43B
EBITDA$3.21B$3.21B$-7.59B$-5.29B$-18.07B
EPS181.00181.00-2122.00-1561.00-7588.00
Gross Margin28.3%28.3%46.9%49.5%14.5%
Operating Margin-97.2%-97.2%-30.9%-56.4%-127.8%
Net Margin18.7%18.7%-60.6%-42.2%-343.2%
Balance Sheet
Debt/Equity0.410.410.180.070.07
Current Ratio1.211.21———
Cash Flow
Free Cash Flow$-7.31B$-7.31B$-7.16B$-10.26B$-12.97B
Returns
ROE1.8%1.8%-32.0%-17.0%-51.5%
Valuation
P/E33.1533.15———
EV/EBITDA12.2012.20———
P/B0.640.640.580.570.41
Growth & Yield
Revenue Growth-53.4%-53.4%-2.6%157.6%—
EPS Growth108.5%108.5%-35.9%79.4%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

43.3%

muy exigente

EPS terminal req.

$532.40

Spread vs growth

65.2%

5Y implied EPS CAGR

28.9%

muy exigente

EPS terminal req.

$644.20

Spread vs growth

79.6%

10Y implied EPS CAGR

19.1%

exigente

EPS terminal req.

$1037.50

Spread vs growth

89.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -25.0%

Total return

-25.0%

Start / end P/E

n/dx → n/dx

EPS bridge

-2122.00 → 181.00

Residual

-25.0%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-25.0%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.